Alkem Laboratories Ltd (NSE: ALKEM, BSE: 539523) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹65,139 Cr, it ranks #169 by market cap among the 6,197 Indian listed companies on FinBizNet, and #10 of 86 in Medicinal Chemicals and Botanical Products. At ₹5,114.00 (as of 16 Nov 2026), the share price is 13.8% below its 52-week high of ₹5,933.50 and 6.3% above its 52-week low of ₹4,811.00. The share price is down 9.4% over one year and down 6.2% over three months.
| Current Price | ₹5,114.00 |
|---|---|
| Market Cap | ₹65,139 Cr |
| NSE Symbol | ALKEM |
| BSE Code | 539523 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 27.5 |
| Return on Equity | 17.56% |
| Return on Assets | 8.43% |
| 52-Week Range | ₹4,811.00 – ₹5,933.50 |
| 1-Year Price Change | -9.4% |
| 3-Month Price Change | -6.2% |
| Beta (1Y) | 0.25 |
| Dividend Yield | 0.38% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.alkemlabs.com |
| Revenue | ₹4,552 Cr |
|---|---|
| Net Profit | ₹667 Cr |
| Net Margin | 14.7% |
| EPS (Basic) | ₹56.48 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alkem Laboratories Ltd reported revenue of ₹4,552 Cr in Q2 FY27, up 13.8% from ₹4,001 Cr in Q2 FY26 and up 21.7% from ₹3,740 Cr in Q1 FY27. It posted a net profit of ₹667 Cr for the quarter, against a net profit of ₹779 Cr in Q2 FY26 (down 14.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹3,144 Cr (Q4 FY25) to ₹4,552 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹4,552 Cr | ₹667 Cr | 14.7% |
| Q1 FY27 | ₹3,740 Cr | ₹521 Cr | 13.9% |
| Q4 FY26 | ₹3,603 Cr | ₹251 Cr | 7.0% |
| Q3 FY26 | ₹3,737 Cr | ₹653 Cr | 17.5% |
| Q2 FY26 | ₹4,001 Cr | ₹779 Cr | 19.5% |
| Q1 FY26 | ₹3,371 Cr | ₹668 Cr | 19.8% |
| Q4 FY25 | ₹3,144 Cr | ₹322 Cr | 10.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 49.70% of Alkem Laboratories Ltd's shares as of Jun 2026, against 53.04% in Jun 2025 (−3.34 percentage points). Delivery averaged 42.6% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.
1. Pharmaceuticals-This segment develops, manufactures, and sells pharmaceutical and nutraceutical products. 2. Investing-0 3. Corporate-This segment invests in real estate for rent. 4. Segment Adjustment-0
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Alkem Laboratories Ltd | ₹65,139 Cr | 27.5 | 17.56% | ₹4,552 Cr | -9.4% |
Listed by market capitalisation. Ratios are shown for context only.
Alkem Laboratories Ltd is trading at ₹5,114.00, with a market capitalisation of ₹65,139 Cr.
Alkem Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Alkem Laboratories Ltd has a P/E of 27.5 and a return on equity of 17.56%.
Alkem Laboratories Ltd is listed on the NSE under the symbol ALKEM and on the BSE under the scrip code 539523.
Alkem Laboratories Ltd's share price is down 9.4% over one year and down 6.2% over three months. Its 52-week range is ₹4,811.00 to ₹5,933.50.
In Q2 FY27, Alkem Laboratories Ltd reported revenue of ₹4,552 Cr and net profit of ₹667 Cr, with basic EPS of ₹56.48 (consolidated, parsed from the company's exchange filing).
Alkem Laboratories Ltd reported revenue of ₹4,552 Cr in Q2 FY27, up 13.8% from ₹4,001 Cr in Q2 FY26 and up 21.7% from ₹3,740 Cr in Q1 FY27.
Promoters held 49.70% of Alkem Laboratories Ltd's shares as of Jun 2026, against 53.04% in Jun 2025 (−3.34 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.